Search
Eterna Therapeutics Inc
ERNAAdd to Watchlist
6.270USD
-0.300-4.46%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
49.24MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-4.46%
5 Days
-10.04%
1 Month
-23.44%
6 Months
+440.52%
Year to Date
+422.50%
1 Year
+213.50%
Key Figures
6.630Open
6.923High
14.17KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.18%Turnover Ratio
6.704Prev. Close
6.260Low
58.89KTurnover
LossP/E Static
20.52P/B
0.00%Div Yield TTM
-145.98%ROA
91.53752wk High
0.58Volume Ratio
-44.55MNet Profit
7.85MShares
-172.0495EPS TTM
2.46Beta
-2514.66%ROE
3.18352wk Low
9.88%Amplitude
83.51%Gross Margin
49.24MMarket Cap
-2.32Reward/Risk
7.81%Risk Rate
TradingKey Stock Score of Eterna Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Eterna Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 133 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 30.00.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Eterna Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Eterna Therapeutics Inc Highlights
StrengthsRisks
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Undervalued
The company’s latest PE is -0.04, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 23.70K shares, increasing 3.06% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.96.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
30.000
Target Price
+347.48%
Upside Space
Eterna Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Eterna Therapeutics Inc Info
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Ticker SymbolERNA
CompanyEterna Therapeutics Inc
CEOLuther (Sanjeev)
Websitehttps://www.ernexatx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Eterna Therapeutics Inc (ERNA)?
The current price of Eterna Therapeutics Inc (ERNA) is 6.27.
What is the symbol of Eterna Therapeutics Inc?
The ticker symbol of Eterna Therapeutics Inc is ERNA.
What is the 52-week high of Eterna Therapeutics Inc?
The 52-week high of Eterna Therapeutics Inc is 91.54.
What is the 52-week low of Eterna Therapeutics Inc?
The 52-week low of Eterna Therapeutics Inc is 3.18.
What is the market capitalization of Eterna Therapeutics Inc?
The market capitalization of Eterna Therapeutics Inc is 292.43K.
Is Eterna Therapeutics Inc (ERNA) currently rated as Buy, Hold, or Sell?
According to analysts, Eterna Therapeutics Inc (ERNA) has an overall rating of Buy, with a price target of 30.00.
What is the Earnings Per Share (EPS TTM) of Eterna Therapeutics Inc (ERNA)?
The Earnings Per Share (EPS TTM) of Eterna Therapeutics Inc (ERNA) is -55.89.